论文部分内容阅读
目的:研究黄鳍金枪鱼胰脏酶解液控制链脲佐菌素(STZ)诱导的糖尿病大鼠血糖和血脂异常的作用,为进一步开发利用金枪鱼胰脏,研制新型辅助降血糖保健食品提供理论依据。方法:用STZ制备糖尿病大鼠模型后分组,给予不同剂量的酶解液,35d后测定各组大鼠空腹血糖、糖化血清蛋白、口服糖耐量及血脂生化指标。结果:与模型组相比,低、中、高剂量组黄鳍金枪鱼胰脏酶解液均能显著地降低糖尿病大鼠的空腹血糖、糖化血清蛋白,改善糖耐量水平;降低总胆固醇、甘油三脂、低密度脂蛋白胆固醇水平,升高高密度脂蛋白胆固醇。结论:黄鳍金枪鱼胰脏酶解液可改善糖尿病大鼠血糖、血脂,促进糖代谢和脂代谢的良性循环。
Objective: To study the effect of yellowfin tuna hydrolyzate on the control of blood glucose and dyslipidemia in streptozotocin (STZ) -induced diabetic rats and to provide a theoretical basis for further development and utilization of tuna pancreas and development of new hypoglycemic health food . Methods: Diabetic rat models were established by STZ group, and different doses of enzymatic hydrolyzate were given. After 35 days, fasting blood glucose, glycosylated serum protein, oral glucose tolerance and blood lipid biochemical indexes were determined. Results: Compared with the model group, the low, medium and high doses of yellowfin tuna pancreatic hydrolyzate can significantly reduce fasting blood glucose, glycosylated serum protein in diabetic rats and improve the level of glucose tolerance; reduce total cholesterol, triglyceride Lipid, low-density lipoprotein cholesterol levels, elevated high-density lipoprotein cholesterol. Conclusion: The yellowfin finfish hydrolyzate can improve the blood sugar, blood fat, promote the sugar metabolism and lipid metabolism in diabetic rats.